IL18 and cystic fibrosis: Also, in marked contrast, the in vitro pre-administration of the other drug combination, IVA/TEZ, for 24 hr, significantly reduced the post-stimulus increments in both IL-18 (p<0.0001, Figure 1C) and IL-1β levels (p=0.0001, Figure 1D), in monocytes of patients with CF.